2024
Understanding and overcoming resistance to immunotherapy in genitourinary cancers
Evans S, Jani Y, Jansen C, Yildirim A, Kalemoglu E, Bilen M. Understanding and overcoming resistance to immunotherapy in genitourinary cancers. Cancer Biology & Therapy 2024, 25: 2342599. PMID: 38629578, PMCID: PMC11028033, DOI: 10.1080/15384047.2024.2342599.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsResistance to immunotherapyImmunotherapy resistanceTargeted therapyGenitourinary (GU) cancersCombined immune checkpoint inhibitorsIntroduction of novel immunotherapiesMechanisms of immunotherapy resistanceOvercome resistance to immunotherapyCancer cellsHost immune profileResponse to immunotherapyNovel targeted therapiesImmune system's rolePredictors of responseAttack cancer cellsImmune system's abilityStandard of careCheckpoint inhibitorsSequential therapyNovel immunotherapiesCombination therapyTreatment failureGU cancersTreatment landscape
2023
Abstract B009: Isolating human RCC tumor cells details evolutionary relationships between cancer cell subsets and a role of OXPHOS in disease progression
Sobierajska E, Medina C, Gregorova P, Vo B, Greenwald R, Jansen C, Larsen C, Master V, Kissick H. Abstract B009: Isolating human RCC tumor cells details evolutionary relationships between cancer cell subsets and a role of OXPHOS in disease progression. Cancer Research 2023, 83: b009-b009. DOI: 10.1158/1538-7445.kidney23-b009.Peer-Reviewed Original ResearchOxidative phosphorylationEvolutionary relationshipsRNA-seqCancer cellsCancer cell subsetsRCC tumor cellsWhole-genome sequencingMutation detection sensitivityDisease progressionUnique to cancer cellsKidney cancer cellsCell differentiation pathsIncreased oxidative phosphorylationCell subsetsEpithelial to mesenchymal transitionGenome sequenceIncreased proliferative stateTumor cellsTumor tissuesScRNA-seqOxidative metabolismAssociated with disease recurrenceCD8 T cell numbersMitochondrial potentialMitochondrial fitness